WallStreetZenWallStreetZen

NASDAQ: CMPX
Compass Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CMPX

Based on 5 analysts offering 12 month price targets for Compass Therapeutics Inc

Min Forecast
$9.00+71.76%
Avg Forecast
$14.20+170.99%
Max Forecast
$30.00+472.52%

Should I buy or sell CMPX stock?

Based on 5 analysts offering ratings for Compass Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CMPX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CMPX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CMPX stock forecasts and price targets.

CMPX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-03
lockedlocked$00.00+00.00%2025-12-03
lockedlocked$00.00+00.00%2025-11-05
lockedlocked$00.00+00.00%2025-10-06
lockedlocked$00.00+00.00%2025-08-12Find Out Why
Raymond James
Bottom 50%
50
BuyReinstates$9.00+71.76%2025-07-01

1 of 1

Forecast return on equity

Is CMPX forecast to generate an efficient return?

Company
6.49%
Industry
248.15%
Market
227.73%
CMPX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CMPX forecast to generate an efficient return on assets?

Company
5.88%
Industry
88.69%
CMPX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CMPX earnings per share forecast

What is CMPX's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$0.46
Avg 2 year Forecast
-$0.50
Avg 3 year Forecast
-$0.43

CMPX revenue forecast

What is CMPX's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$11.0M
Avg 3 year Forecast
$70.6M

CMPX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CMPX$5.24$14.20+170.99%Strong Buy
KURA$10.63$29.20+174.69%Strong Buy
MPLT$20.35$31.00+52.33%Strong Buy
RAPT$34.03$54.13+59.05%Strong Buy
MRVI$3.59$4.83+34.62%Strong Buy
View Top Biotech Stocks

Compass Therapeutics Stock Forecast FAQ

Is Compass Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CMPX) stock is to Strong Buy CMPX stock.

Out of 5 analysts, 3 (60%) are recommending CMPX as a Strong Buy, 2 (40%) are recommending CMPX as a Buy, 0 (0%) are recommending CMPX as a Hold, 0 (0%) are recommending CMPX as a Sell, and 0 (0%) are recommending CMPX as a Strong Sell.

If you're new to stock investing, here's how to buy Compass Therapeutics stock.

What is CMPX's earnings growth forecast for 2025-2027?

(NASDAQ: CMPX) Compass Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.67%.

Compass Therapeutics's earnings in 2025 is -$65,806,000.On average, 13 Wall Street analysts forecast CMPX's earnings for 2025 to be -$81,976,643, with the lowest CMPX earnings forecast at -$102,839,867, and the highest CMPX earnings forecast at -$69,099,427. On average, 13 Wall Street analysts forecast CMPX's earnings for 2026 to be -$88,166,244, with the lowest CMPX earnings forecast at -$122,013,402, and the highest CMPX earnings forecast at -$39,218,593.

In 2027, CMPX is forecast to generate -$75,964,904 in earnings, with the lowest earnings forecast at -$174,304,860 and the highest earnings forecast at -$20,543,073.

What is CMPX's revenue growth forecast for 2025-2027?

(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 100.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.5%.

Compass Therapeutics's revenue in 2025 is $0.On average, 12 Wall Street analysts forecast CMPX's revenue for 2025 to be $0, with the lowest CMPX revenue forecast at $0, and the highest CMPX revenue forecast at $0. On average, 12 Wall Street analysts forecast CMPX's revenue for 2026 to be $1,965,198,365, with the lowest CMPX revenue forecast at $0, and the highest CMPX revenue forecast at $7,339,479,639.

In 2027, CMPX is forecast to generate $12,556,708,677 in revenue, with the lowest revenue forecast at $5,351,159,201 and the highest revenue forecast at $31,899,567,994.

What is CMPX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CMPX) forecast ROA is 5.88%, which is lower than the forecast US Biotechnology industry average of 88.69%.

What is CMPX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CMPX price target, the average CMPX price target is $14.20, with the highest CMPX stock price forecast at $30.00 and the lowest CMPX stock price forecast at $9.00.

On average, Wall Street analysts predict that Compass Therapeutics's share price could reach $14.20 by Dec 3, 2026. The average Compass Therapeutics stock price prediction forecasts a potential upside of 170.99% from the current CMPX share price of $5.24.

What is CMPX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CMPX) Compass Therapeutics's current Earnings Per Share (EPS) is -$0.45. On average, analysts forecast that CMPX's EPS will be -$0.46 for 2025, with the lowest EPS forecast at -$0.58, and the highest EPS forecast at -$0.39. On average, analysts forecast that CMPX's EPS will be -$0.50 for 2026, with the lowest EPS forecast at -$0.69, and the highest EPS forecast at -$0.22. In 2027, CMPX's EPS is forecast to hit -$0.43 (min: -$0.98, max: -$0.12).

What is CMPX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CMPX) forecast ROE is 6.49%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.